San Diego-primarily based Viking Therapeutics marked alone as a serious competitor inside the weight loss drug marketplace in February following revealing promising data from a mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs w